Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co
about
Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer?Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trialsEvaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry.Recent advances in antithrombotic therapy after acute coronary syndrome.Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.Healing the injured vessel wall using microRNA-facilitated gene delivery.Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention.Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trialsImplementing clinical trials on an international platform: challenges and perspectives.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsAntiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trialContemporary use of dual antiplatelet therapy for preventing cardiovascular eventsBalancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents.Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.Causes of late mortality with dual antiplatelet therapy after coronary stents.Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trialRisk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy.TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.Cost-effectiveness of oral antiplatelet agents--current and future perspectives.Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature.P2Y12 platelet inhibition in clinical practice.Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.Stent thrombosis: an overview.Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.Controversies in the use & implementation of drug-eluting stent technology.Dual antiplatelet therapy dilemmas: duration and choice of antiplatelets in acute coronary syndromes.Use of antiplatelet agents in patients with atherosclerotic disease.Drug-eluting versus bare-metal coronary stents: where are we now?Cardiovascular medication use following percutaneous coronary intervention: the Australian experience.Novel antiplatelet agents in acute coronary syndrome.Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Antiplatelet therapy after coronary stenting.Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
P2860
Q26852812-978428B5-650C-492B-A6AE-9D501A2C9898Q26999848-E51498F7-5DD8-4EB7-9FD4-D060063F3BA5Q30870018-8A099FE3-F0EA-4C15-83A9-8DA81227DD46Q33590548-6EF28D99-56A5-46E8-ABE4-C01DB54A76BBQ33613297-414416F4-02A0-4488-8834-7A530D97E699Q34055438-EDF08708-4AA5-4AA8-8AD6-DA72B70E761AQ34117575-63D70A43-D532-4895-B231-BA64DA5EEC7DQ35101374-DD6607DA-DF78-48F0-A85C-B11592392B13Q35530065-18A563EB-A682-45E5-A23F-3361F7EF2E58Q35541045-73753AFB-1EC1-4B62-90E6-445B44A38EB9Q35663409-62A92606-D425-4148-B01D-131F0D3A96CFQ35783487-EC796106-B6B0-4A50-8F3C-16E31FE2AB0BQ35783499-E220D1EF-F458-423A-8F61-1DED9FCD996AQ35963386-33CED30A-D5BC-4163-82CB-781A8E8B600CQ36347982-58184A97-E102-4DA1-8B70-A9E67F290BC8Q36369122-386B147C-E065-43C9-8B20-CC3D117CBC77Q36573521-21E684AB-E39D-4A0A-B022-CFE357F6BFB7Q36688217-2F36DDCD-0A7F-4922-924F-B6AE124CB6DEQ36995923-FF0A8D94-E299-41D7-BB62-3A94F576B42CQ37457934-A6B919AB-4C05-4F4C-92D9-0A7A471DB4DBQ37913974-B7948369-3215-4B34-8CBF-E55E31392D39Q37953153-43BDD7E3-612C-4AB4-ACD7-8347BE8EF1C1Q37969927-EEE915AD-CBD7-4699-8E97-DA01FF823D6DQ37998114-C31C2118-AEF3-4B66-A7D9-5A8100018B9CQ38014978-6DF45B20-D2A8-4D07-81BF-AEF3AD25929EQ38017567-F41CCC81-77CF-4CEC-9A56-B4748D50EF78Q38054689-E2496FDD-F7C6-49D2-B3D6-82190F3E906DQ38079934-F3E86EA7-99E2-4994-978C-67B10A44E82FQ38137724-A5364CA0-2EE1-4858-9E5E-CAD3D59B35FDQ38151446-40E1E2A6-2F30-4172-8972-388DDC807D5FQ38162864-3DA7D044-C764-4F2B-8B5D-6A65D3053956Q38176088-E12894E9-9236-4214-9813-1248EAA4C5B7Q38257119-FBBC4A73-8AB3-49E9-A6EA-4A8585F8C0A5Q38379410-E128B7AF-23E3-4635-9474-4F0E7CBFCE67Q38380436-17393BBF-FF61-4CD7-B280-AAC5284DEB30Q38388236-2004467C-5F4F-4418-80B4-5511A5B25349Q38436521-20F64D3F-CC20-4CB8-926D-5349C14DCFD2Q38974884-0999E35A-9741-4C8E-89EC-7D98C9967EFFQ39498712-325EA65C-1FDD-478E-949C-09F6ACA7A572Q41451789-FAAB37DA-7C35-4A1E-964D-20E2DED63383
P2860
Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous co
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Rationale and design of the du ...... cts undergoing percutaneous co
@en
Rationale and design of the du ...... cts undergoing percutaneous co
@nl
type
label
Rationale and design of the du ...... cts undergoing percutaneous co
@en
Rationale and design of the du ...... cts undergoing percutaneous co
@nl
prefLabel
Rationale and design of the du ...... cts undergoing percutaneous co
@en
Rationale and design of the du ...... cts undergoing percutaneous co
@nl
P2093
P1476
Rationale and design of the du ...... cts undergoing percutaneous co
@en
P2093
David J Cohen
David R Holmes
Dean J Kereiakes
Donald E Cutlip
Laura Mauri
Michael Pencina
Sharon-Lise T Normand
Stephen D Wiviott
P304
1035-41, 1041.e1
P356
10.1016/J.AHJ.2010.07.038
P407
P577
2010-12-01T00:00:00Z